Exemestane prevents 65 percent of invasive breast cancers in postmenopausal women
from Internal Medicine News
A daily dose of the aromatase inhibitor exemestane reduced invasive breast cancers by 65 percent in a placebo-controlled chemoprevention trial that enrolled 4,560 postmenopausal women considered at increased risk of the disease. Pre-invasive breast cancers and precancerous lesions also were much less common at a median follow-up of three years in the study, which is expected to reopen a stalled conversation between women and their physicians regarding the risks and benefits of chemoprevention.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063